TY - JOUR T1 - Modulation of Chemokine Receptor Function by Cholesterol: New Prospects for Pharmacological Intervention JF - Molecular Pharmacology JO - Mol Pharmacol SP - 331 LP - 338 DO - 10.1124/mol.116.107151 VL - 91 IS - 4 AU - Daniel F. Legler AU - Christoph Matti AU - Julia M. Laufer AU - Barbara D. Jakobs AU - Vladimir Purvanov AU - Edith Uetz-von Allmen AU - Marcus Thelen Y1 - 2017/04/01 UR - http://molpharm.aspetjournals.org/content/91/4/331.abstract N2 - Chemokine receptors are seven transmembrane-domain receptors belonging to class A of G-protein-coupled receptors (GPCRs). The receptors together with their chemokine ligands constitute the chemokine system, which is essential for directing cell migration and plays a crucial role in a variety of physiologic and pathologic processes. Given the importance of orchestrating cell migration, it is vital that chemokine receptor signaling is tightly regulated to ensure appropriate responses. Recent studies highlight a key role for cholesterol in modulating chemokine receptor activities. The steroid influences the spatial organization of GPCRs within the membrane bilayer, and consequently can tune chemokine receptor signaling. The effects of cholesterol on the organization and function of chemokine receptors and GPCRs in general include direct and indirect effects (Fig. 1). Here, we review how cholesterol and some key metabolites modulate functions of the chemokine system in multiple ways. We emphasize the role of cholesterol in chemokine receptor oligomerization, thereby promoting the formation of a signaling hub enabling integration of distinct signaling pathways at the receptor-membrane interface. Moreover, we discuss the role of cholesterol in stabilizing particular receptor conformations and its consequence for chemokine binding. Finally, we highlight how cholesterol accumulation, its deprivation, or cholesterol metabolites contribute to modulating cell orchestration during inflammation, induction of an adaptive immune response, as well as to dampening an anti-tumor immune response. ER -